Ann: Annual Report, page-4

I think that the next quarterly report is definitely the one to look at.
The reported progress during the year would indicate that there is more good news on the way as a result of the big second half turnaround. The question remains as to how much of this turnaround is from the old TUTA business as opposed to the Medivet business. The segment reporting seems to indicate that the Medivet side is contributing a lot less than expected, especially Australia. Was it a good buy?
It seems to me that TUTA must have really turned the corner! I will have a look at some of the overheads and offer some further comments later.